Drug Approval | February 20, 2025
Orchid Pharma's Alathur API facility successfully completes USFDA inspection
The Alathur facility specializes in the production of Cephalosporin antibiotics
The Alathur facility specializes in the production of Cephalosporin antibiotics
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
ALPLA is going to manufacture high-quality plastic bottles, preforms, matching closures and injection-molded parts in Chachoengsao using all core technologies
Peter Bains has over three decades of experience in the biotech and pharmaceutical industry
_256_384.jpg)
Hikal Limited announces the completion of the US Food and Drug Administration (USFDA) inspection at its Jigani unit, Bengaluru
During the quarter, the company posted Revenue from operations at Rs. 5,269 crore as compared to Rs. 4,505 crore in Q3 FY25, posting a growth of 17 per cent
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
Subscribe To Our Newsletter & Stay Updated
